Vifor Pharma
Vifor Pharma Group is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of Vifor Pharma, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics. Activity. Vifor Pharma is active in the treatment of iron deficiency and iron deficiency anaemia. The Group also has a focus on the management of conditions in nephrology, cardiology and rare diseases. Iron deficiency treatments Ferinject and Injectafer were accountable for more than a third of its revenues in 2021. In 2017, Vifor Pharma Group was listed (ticker  symbol VIFN) on the Swiss Stock Exchange (SIX) after splitting up the former Galenica Group. This was completed through an initial public offering (IPO) of Galenica Santé (listed as GALE). Vifor Pharma Group is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA). Structure and operations. Vifor Pharma Group is present in North and South America, Europe, the Middle East and Asia Pacific and works with over 100 partners all around the world. Vifor Pharma  Group develops, manufactures and markets pharmaceutical products including prescription and non-prescription products. The Group's businesses include Vifor Pharma, focused on iron deficiency and iron deficiency anaemia, and Vifor Fresenius Medical Care Renal Pharma, focused on kidney disease patients, including anaemia, mineral and bone management, cardio-renal conditions, and rare diseases. Across the Group there are manufacturing and R&D sites in Switzerland and Portugal. Raw materials are sourced globally with active pharmaceutical ingredients manufactured in Switzerland, Germany and Austria. Final products are manufactured by partners across Europe, Turkey and North America.